Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2001 | 06-2001 | 03-2001 | 12-2000 | 09-2000 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,040 | -18,020 | -6,270 | -18,280 | -12,370 |
| Depreciation Amortization | 2,510 | 1,540 | 760 | 3,020 | 1,850 |
| Other Working Capital | -5,540 | -5,800 | -2,730 | -4,490 | -5,470 |
| Other Operating Activity | 2,170 | 5,220 | 120 | 450 | 870 |
| Operating Cash Flow | $-25,900 | $-17,060 | $-8,120 | $-19,300 | $-15,120 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -50 | -30 | -5 | -50 | 0 |
| Other Investing Activity | -19,750 | -17,550 | -10,545 | -44,470 | -13,940 |
| Investing Cash Flow | $-19,800 | $-17,580 | $-10,550 | $-44,520 | $-13,940 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 4,440 | -260 | -220 | 78,130 | 77,660 |
| Financing Cash Flow | $4,440 | $-260 | $-220 | $78,130 | $77,660 |
| Exchange Rate Effect | 180 | 0 | 0 | 0 | 0 |
| Beginning Cash Position | 55,330 | 55,330 | 55,330 | 41,020 | 41,020 |
| End Cash Position | 14,240 | 20,410 | 36,420 | 55,330 | 89,610 |
| Net Cash Flow | $-41,080 | $-34,910 | $-18,900 | $14,300 | $48,590 |
| Free Cash Flow | |||||
| Operating Cash Flow | -25,900 | -17,060 | -8,120 | -19,300 | -15,120 |
| Free Cash Flow | -25,900 | -17,060 | -8,120 | -19,300 | -15,120 |